Liestal, Switzerland

Markus Riederer

USPTO Granted Patents = 4 



Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2010-2012

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: **Markus Riederer: A Pioneer in Pharmaceutical Innovations**

Introduction

Markus Riederer, a notable inventor based in Liestal, Switzerland, has made significant contributions to the field of pharmacology. With a total of four patents to his name, Riederer continues to push the boundaries of pharmaceutical science, focusing particularly on innovative compounds that address critical health issues.

Latest Patents

Riederer’s latest patents include groundbreaking work on 2-sulfanyl-benzoimidazol-1-yi-acetic acid derivatives, which serve as CRTH2 antagonists. This invention specifically relates to the development of these derivatives for the treatment of prostaglandin-mediated diseases, demonstrating their potential application in addressing complex health challenges. Another significant patent involves novel tetrahydro-1H-carbazole derivatives, which are also aimed at pharmaceutical compositions. This invention not only consists of the preparation processes for these compounds but also explores their medical applications, benefiting patients in need.

Career Highlights

Currently, Markus Riederer is associated with Actelion Pharmaceuticals Ltd., where his research and innovations are contributing to the advancement of medicinal chemistry. His work exemplifies a commitment to improving therapeutic options and enhancing patient outcomes through targeted pharmaceutical solutions.

Collaborations

Riederer collaborates closely with fellow professionals, including Heinz Fretz and Anja Fecher. Their combined expertise in the field fosters a creative environment conducive to groundbreaking research and innovative discoveries in the pharmaceutical sector.

Conclusion

In summary, Markus Riederer stands out as a key figure in the realm of pharmaceutical inventions. His contributions, particularly in the area of novel chemical compounds, showcase how dedicated researchers can make a substantial impact on medicine and patient care. As he continues his work with Actelion Pharmaceuticals Ltd., the medical community eagerly anticipates the future innovations that will emerge from his efforts.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…